Living Cell Technologies Limited

Company Announcement

Appendix 4C Quarterly Cash Flow Report 30 June 2012

23 July 2012: Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY), announced today the quarterly cash flow report for the quarter ended 30 June 2012. The Appendix 4C is attached. The cash balance at the end of the quarter was $3,170,000 compared to $2,662,000 at 31 March 2012. This increase reflects the net proceeds from the Share Purchase Plan of $1,013,000 and the services fee received from Diatranz Otsuka Limited (DOL) for the continuing development cost of DIABECELL®, partially offset by the cost of developing NTCELL for the treatment of Parkinson's disease.

Net operating cash flow in the quarter was ($491,000) compared to $95,000 last quarter. Receipts from customers were $1,529,000 reflecting the services provided to DOL (last quarter $1,868,000). Operating payments were $2,040,000 compared to $1,962,000 last quarter. They include payments for the services provided to DOL for the development of DIABECELL, costs of the NTCELL clinical trial application and continuing preparation for the Good Manufacturing Practice manufacture of NTCELL for the clinical trial in the first quarter of 2013.

Capital expenditure was $2,000 in the quarter, compared to $0 last quarter as DOL is investing in fixed assets.

- Ends –

For further information: www.lctglobal.com

At the company:	**Media enquiries:**
Dr Andrea Grant, Chief Executive Tel: +64 9 270 7941 Mobile: +64 21 078 5421 agrant@lctglobal.com John Cowan, Head of Finance & Administration Tel: +64 9 276 2690 Mobile: +64 21 469000 jcowan@lctglobal.com	Sally Raudon Botica Butler Raudon Partners Tel: +64 9 303 3862 Mobile: +64 21 402 502 sallyr@botica.co.nz

About Living Cell Technologies

Living Cell Technologies (LCT) leads the world in developing cell-based therapeutics to treat diseases with high unmet clinical need. Its proprietary cell encapsulation technology IMMUPEL™ allows for cell transplantation without the need for immunosuppressant drugs.

LCT's lead therapeutic candidate DIABECELL® is indicated for the treatment of patients with type 1 diabetes, especially those suffering from life threatening episodes of unaware

hypoglycaemia (low blood sugar), a dangerous and potentially fatal diabetes complication. DIABECELL is currently in Phase II clinical trials in both New Zealand and Argentina.

In 2011, LCT formed a partnership with Otsuka Pharmaceutical Factory Inc (OPF) in which the joint venture Diatranz Otsuka Limited (NZ) was established. Valued at A$50m on formation, LCT vested the DIABECELL product and associated IP into the JV, while OPF vested A$25m to fund the final phase of development of DIABECELL through to market approval. Both LCT and OPF are 50:50 shareholders in the current and future value generated by DIABECELL and the associated IP.

LCT has also developed NTCELL, a choroid plexus cell product, to treat neurodegenerative diseases such as Parkinson's disease and stroke. NTCELL's trial results indicate potential for protecting, repairing and possibly regenerating brain tissue which would otherwise die.

LCT is incorporated in Australia. Research and development, operations and manufacturing facilities are based in New Zealand.

LCT Disclaimer